Cyclosporine is a long-established immunosuppressant medicine that helps prevent the body's immune system from rejecting a transplanted organ, and is also used for certain autoimmune conditions. It belongs to a class of medicines called calcineurin inhibitors, the same class as tacrolimus, though the two are not interchangeable milligram-for-milligram. It is a prescription-only medicine with a narrow therapeutic window.

• Therapeutic Class: Immunosuppressant (systemic).

• Pharmacological Class: Calcineurin inhibitor.

• Drug Family: Cyclic polypeptide immunosuppressants (derived from a fungal source).

• ATC Classification: L04AD01 (Ciclosporin).

• Approved: Prevention of organ rejection in kidney, liver, and heart transplants (in combination with corticosteroids and other immunosuppressants); severe, active rheumatoid arthritis in patients who haven't responded adequately to methotrexate; and severe plaque psoriasis in adults who are candidates for systemic therapy.

• Commonly used for: Transplant recipients as part of a combination anti-rejection regimen, and patients with severe autoimmune skin or joint conditions not controlled by other treatments.

• Off-label use (only under medical guidance): Sometimes used for other autoimmune or inflammatory conditions (e.g., certain kidney diseases, atopic dermatitis) under specialist care.

●       Oral capsules (microemulsion formulation): commonly 25 mg and 100 mg.

●       Oral solution: for patients unable to take capsules, dosed by body weight.

●       Injection (intravenous): used short-term when oral dosing isn't possible.

Cyclosporine binds to a protein inside immune cells called cyclophilin, and this complex then blocks an enzyme called calcineurin — the same target as tacrolimus, though the two drugs bind different carrier proteins first. Blocking calcineurin prevents T-cells (key immune cells involved in organ rejection and autoimmune inflammation) from activating, reducing the immune response responsible for transplant rejection or autoimmune tissue damage.

• Standard starting dose (transplant, adults): Typically 9-15 mg/kg/day given as a divided dose starting 4-12 hours before transplant, then continued and adjusted based on blood trough levels.

• Condition-wise dose (rheumatoid arthritis): Typically starts around 2.5 mg/kg/day, divided into two doses, adjusted based on response and tolerability.

• Route: Oral (capsule or solution), or intravenous infusion short-term when oral dosing isn't tolerated.

• Missed dose: Take as soon as remembered unless close to the next dose; contact the treating team rather than doubling up, given the narrow therapeutic window.

• Overdose: Can cause significant kidney toxicity or other exaggerated side effects; requires urgent medical attention and blood level monitoring.

• Common: High blood pressure, tremor, headache, increased hair growth (hirsutism), gum overgrowth, and elevated cholesterol.

• Serious: Kidney toxicity (both acute and chronic), increased risk of infections and certain cancers (including lymphoma and skin cancers) due to immune suppression, and neurotoxicity in severe cases.

• Emergency symptoms: Signs of serious infection (fever, chills), severe tremor or seizures, significant swelling or reduced urine output, or very high blood pressure.

• Recovery advice: Regular blood level monitoring guides dose adjustments — levels too low risk organ rejection or disease flare, while levels too high increase toxicity, so dosing is tailored to trough blood results rather than symptoms alone.

• Pregnancy: Used when clearly needed in transplant patients, under close specialist supervision, weighing risks of stopping immunosuppression against medicine-related risks.

• Breastfeeding: Generally not recommended without specific medical guidance.

• Liver disease: Dose adjustment may be needed; liver function is monitored during treatment.

• Kidney disease: Used with particular caution, given cyclosporine's own well-documented potential to affect kidney function; closely monitored.

• Elderly: Used with caution; blood pressure and kidney function are monitored particularly closely in this age group.

• Children: Used in pediatric transplant and certain autoimmune settings under specialist care, with weight-based dosing.

●       Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, grapefruit juice): significantly increase cyclosporine levels, raising toxicity risk; dose reduction and closer monitoring are needed.

●       Strong CYP3A4 inducers (e.g., rifampin, phenytoin, St. John's Wort): can significantly reduce cyclosporine levels, risking organ rejection or disease flare.

●       Other nephrotoxic drugs (e.g., NSAIDs, aminoglycosides, amphotericin B): increase the risk of kidney toxicity when combined.

●       Live vaccines: should generally be avoided during treatment due to the immunosuppressive effect.

●       Cyclosporine trough blood levels, monitored frequently, especially early in treatment or after any dose/medication change.

●       Kidney function tests and blood pressure regularly.

●       Cholesterol and lipid monitoring.

●       Monitoring for signs of infection and, over the longer term, skin and other cancer screening given cumulative immunosuppression.

Tacrolimus (another calcineurin inhibitor, generally with a different side-effect emphasis), Sirolimus, Everolimus (mTOR inhibitors, different mechanism).

Typically combined with other immunosuppressants — such as mycophenolate mofetil/sodium, azathioprine, or an mTOR inhibitor, plus corticosteroids — as part of a multi-drug transplant regimen; in rheumatoid arthritis, sometimes combined with methotrexate under specialist supervision.

●       Organ Transplant / Anti-Rejection Medicines

●       Calcineurin Inhibitors

●       Severe Autoimmune Disease Treatments

1. The Rising Tide of Autoimmune Disorders: Why Now?

2.  Autoimmune Myths vs. Facts: What’s the Truth?

3. Medication Process Of Kidney Transplant Patients

4. Kidney Transplantation Procedure And Cost In India

5. Top Immunosuppressant Medicines After Kidney Transplant -guide

6. Medication Process Of Kidney Transplant Patients

1. https://www.accessdata.fda.gov/drugsatfda_docs/label

2. https://www.drugs.com/dosage/cyclosporine.html

The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your doctor to know if this treatment is appropriate for your condition.